Most people do not associate a breathing problem during sleep with damage to their kidneys. The connection is not intuitive. But the kidneys are exquisitely sensitive to the two things that untreated sleep apnoea delivers in large amounts, night after night: oxidative stress from repeated oxygen crashes, and sustained activation of the renin-angiotensin-aldosterone system (the body's blood pressure and fluid regulation mechanism, which OSA drives into chronic overdrive). These stresses damage kidney tissue directly and accelerate the decline of kidney function in those who already have kidney disease.
OSA and the Risk of Developing Kidney Disease
A meta-analysis pooling results from multiple observational studies found that OSA is associated with a 77 per cent higher odds of chronic kidney disease — an odds ratio of 1.77. To translate that into real-world terms: chronic kidney disease at any stage affects roughly 1 in 7 UK adults (approximately 14 per cent). With untreated OSA, that risk rises to roughly 1 in 4. That is not a minor elevation. It represents a substantial shift in the absolute probability of developing a condition that, in its advanced stages, requires dialysis or transplantation.
For people who already have type 2 diabetes — a group at substantially elevated baseline kidney risk — OSA nearly doubles the odds of developing diabetic kidney disease specifically: an odds ratio of 1.92 for diabetic nephropathy in OSA patients with diabetes. This means that for a diabetic patient trying to protect their kidneys, failing to screen for and treat sleep apnoea leaves a major modifiable risk factor unaddressed.
A Mendelian randomisation study — a type of analysis that uses people's genetic makeup as a natural experiment to test whether one thing genuinely causes another, rather than simply being associated with it — found evidence for a causal effect of OSA on kidney function decline. This is important because it tells us the relationship is not simply explained by the fact that both conditions are common in overweight, middle-aged people with hypertension. OSA is independently driving kidney damage through its own biological mechanisms.
Chronic kidney disease affects roughly 1 in 7 UK adults. With untreated OSA, the evidence puts that closer to 1 in 4. And having both conditions simultaneously more than doubles mortality compared with kidney disease alone.
Accelerated Kidney Function Decline
Beyond the risk of developing kidney disease, OSA also accelerates the pace at which kidney function declines in those already affected. Kidney function is measured by estimated glomerular filtration rate (eGFR) — a calculation of how efficiently the kidneys are filtering the blood. A normal eGFR is above 90. Advanced kidney disease begins below 30. The rate of annual eGFR decline is a key clinical predictor of progression to kidney failure.
Studies following OSA patients over time have found that the degree of nocturnal oxygen desaturation — how low oxygen levels fall during apnoea events — independently predicts how rapidly eGFR falls. The more severe the overnight oxygen drops, the faster the kidney function declines. This dose-response relationship, where the severity of the exposure predicts the severity of the outcome, is exactly what you would expect if the intermittent hypoxia is genuinely driving the kidney damage rather than simply coinciding with it.
The Combined Effect: OSA Plus Kidney Disease
When the two conditions coexist, the combination is considerably more dangerous than either alone. Compared with patients who have kidney disease without OSA, those with both conditions have more than double the mortality risk. An odds ratio of 2.09 for all-cause mortality in people with CKD and OSA together means that the coexistence of both conditions does not simply add risks together — it multiplies them.
The mechanism is partly vascular. OSA drives hypertension (high blood pressure), and hypertension is one of the two main causes of kidney damage, alongside diabetes. A patient with both OSA-driven hypertension and existing kidney disease is facing compounding kidney stress: the hypertension is damaging kidney filtering units (glomeruli) while the hypoxia from OSA is simultaneously causing direct oxidative injury to renal tubules — the parts of the kidney responsible for reabsorbing useful substances from the filtrate before it becomes urine.
Kidney Stones and Gout
Two additional renal and metabolic consequences of OSA deserve mention. OSA patients have a 17 per cent higher risk of kidney stones compared with those without the condition. The mechanism involves OSA-driven acidosis (the blood becoming more acidic from oxygen disruption), which promotes uric acid crystallisation and calcium oxalate deposition in the urine — the two most common types of kidney stone material.
Closely related is gout, which results from elevated uric acid levels (hyperuricaemia) creating urate crystal deposits in joints, most characteristically the big toe but also the knees and ankles. OSA independently elevates uric acid levels — the intermittent hypoxia increases uric acid production as a metabolic by-product — and this produces elevated gout risk in OSA patients independently of diet, alcohol, and other established gout risk factors. CPAP therapy has been shown to reduce serum uric acid levels in OSA patients in randomised trials, which is a clinically important finding for patients with gout who are also discovered to have OSA.
What Treatment Does
The evidence on CPAP and kidney outcomes is encouraging but not as extensive as for cardiovascular or metabolic outcomes. Several studies have reported that consistent CPAP use is associated with slower eGFR decline and reduced proteinuria (protein in the urine, which is a marker of kidney damage) compared with untreated controls. These are observational findings rather than randomised trial results, so they need to be interpreted cautiously. What is clearer is that the downstream consequences of OSA on blood pressure, insulin resistance, and systemic inflammation — all of which damage kidneys — are meaningfully reduced by consistent treatment. Treating the OSA is not sufficient protection for someone with advanced kidney disease, but it removes a significant modifiable driver of ongoing kidney damage in someone who has both conditions.
References
[1] Cai A et al. Obstructive sleep apnea and risk of kidney disease: a systematic review and meta-analysis. Sleep and Breathing. 2020. Multiple observational studies; OR 1.77 for CKD in OSA patients; OR 1.92 for diabetic nephropathy in diabetic OSA patients.
[2] Xu Z et al. Causal relationship between sleep apnea and renal function: a bidirectional Mendelian randomization study. Frontiers in Endocrinology. 2023. Bidirectional MR; univariable MR confirmed OSA causally associated with impaired kidney function (eGFR decline); no reverse causation detected.
[3] Chu H et al. Obstructive sleep apnea and the risk of chronic kidney disease: a population-based cohort study. Sleep. 2015. Large Taiwanese cohort; hazard ratio 1.41 for CKD incidence in OSA patients over follow-up; dose-dependent with AHI severity.
[4] Ding N et al. Association of sleep apnea and mortality in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrology Dialysis Transplantation. 2022. Meta-analysis; OR 2.09 for all-cause mortality in CKD patients with OSA versus CKD without OSA.
[5] Wang K et al. Effect of continuous positive airway pressure on uric acid in patients with obstructive sleep apnea: a meta-analysis. Frontiers in Endocrinology. 2022. Meta-analysis of RCTs; CPAP significantly reduced serum uric acid in OSA patients (weighted mean difference -0.35 mg/dL); largest effect in severe OSA.
[6] Lee J et al. The association between obstructive sleep apnea and nephrolithiasis: a systematic review and meta-analysis. Journal of Endourology. 2021. Meta-analysis; OSA associated with 17% higher risk of kidney stones (OR 1.17).
Contact Professor Vik Veer
If you would like to discuss a sleep assessment or arrange a consultation, please use the details below.
Private secretary: 0207 458 4584